ATE206927T1 - Aufnehmbare zubereitungen enthaltend wasserlösliche, hochviskose cellulosether - Google Patents

Aufnehmbare zubereitungen enthaltend wasserlösliche, hochviskose cellulosether

Info

Publication number
ATE206927T1
ATE206927T1 AT92301720T AT92301720T ATE206927T1 AT E206927 T1 ATE206927 T1 AT E206927T1 AT 92301720 T AT92301720 T AT 92301720T AT 92301720 T AT92301720 T AT 92301720T AT E206927 T1 ATE206927 T1 AT E206927T1
Authority
AT
Austria
Prior art keywords
soluble
levels
compositions
containing water
highly viscous
Prior art date
Application number
AT92301720T
Other languages
English (en)
Inventor
Jennifer B Dressman
Christos Reppas
Stephen W Tobey
Cynthia W Sowle
Original Assignee
Univ Michigan
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27098725&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE206927(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Michigan, Dow Chemical Co filed Critical Univ Michigan
Application granted granted Critical
Publication of ATE206927T1 publication Critical patent/ATE206927T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D13/00—Finished or partly finished bakery products
    • A21D13/80—Pastry not otherwise provided for elsewhere, e.g. cakes, biscuits or cookies
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/14—Organic oxygen compounds
    • A21D2/18—Carbohydrates
    • A21D2/188—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AT92301720T 1991-03-01 1992-02-28 Aufnehmbare zubereitungen enthaltend wasserlösliche, hochviskose cellulosether ATE206927T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66338191A 1991-03-01 1991-03-01
US87060192A 1992-02-21 1992-02-21

Publications (1)

Publication Number Publication Date
ATE206927T1 true ATE206927T1 (de) 2001-11-15

Family

ID=27098725

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92301720T ATE206927T1 (de) 1991-03-01 1992-02-28 Aufnehmbare zubereitungen enthaltend wasserlösliche, hochviskose cellulosether

Country Status (16)

Country Link
EP (1) EP0502666B2 (de)
JP (1) JP3436537B2 (de)
KR (1) KR100227002B1 (de)
AT (1) ATE206927T1 (de)
AU (2) AU669654B2 (de)
CA (1) CA2062091C (de)
DE (1) DE69232126T3 (de)
ES (1) ES2168256T3 (de)
FI (1) FI933809L (de)
HU (1) HU222487B1 (de)
IE (1) IE920660A1 (de)
IL (1) IL101113A (de)
MX (1) MX9200888A (de)
NO (1) NO304968B1 (de)
NZ (1) NZ241778A (de)
WO (1) WO1992015312A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721221A (en) * 1991-03-08 1998-02-24 Regents Of The University Of Minnesota Lowering blood cholesterol levels using water soluble cellulose ethers
US5281584A (en) * 1992-02-28 1994-01-25 The Dow Chemical Company Effect of particle-size distribution of cellulose ethers on palatability of compositions
US6432442B1 (en) * 1998-02-23 2002-08-13 Mcneil-Ppc, Inc. Chewable product
US6899892B2 (en) 2001-12-19 2005-05-31 Regents Of The University Of Minnesota Methods to reduce body fat
CA2666670A1 (en) * 2006-10-20 2008-05-02 Dow Global Technologies Inc. Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome
ITFI20120268A1 (it) 2012-12-03 2014-06-04 Diopeite Consulting Ltd Composizioni farmaceutiche per il trattamento dell'obesita'
US20160231334A1 (en) * 2013-10-28 2016-08-11 The Forsyth Institute Compositions and Methods for Evaluating Metabolic Syndrome and Related Diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802741A (en) * 1953-09-21 1957-08-13 Dow Chemical Co Cake mixes containing water-soluble cellulose ethers
US3709876A (en) * 1972-04-10 1973-01-09 Dow Chemical Co Water soluble hydroxyethyl methyl cellulose ether thickener for latex paint
US4284649A (en) * 1977-11-22 1981-08-18 Wiczer Sol B Thickened gelatinous edible alcoholic medicated carrier
US4451490A (en) * 1982-03-08 1984-05-29 General Foods Corporation High quality, reduced-calorie cake containing cellulose and process thereof
NZ207125A (en) * 1983-02-17 1986-07-11 Merrell Pharma Inc Bulk laxative composition containing water-soluble cellulose ether
FI895708A7 (fi) * 1989-02-10 1990-08-11 Alko Ab Oy Vesiliukoinen hajoamistuote

Also Published As

Publication number Publication date
IL101113A (en) 1999-11-30
CA2062091A1 (en) 1992-09-02
EP0502666A1 (de) 1992-09-09
FI933809A7 (fi) 1993-10-01
MX9200888A (es) 1994-07-29
AU1127492A (en) 1992-08-27
DE69232126D1 (de) 2001-11-22
EP0502666B2 (de) 2007-11-21
DE69232126T2 (de) 2002-06-27
FI933809L (fi) 1993-10-01
HUT67327A (en) 1995-03-28
NO304968B1 (no) 1999-03-15
ES2168256T3 (es) 2002-06-16
JPH06507393A (ja) 1994-08-25
WO1992015312A1 (en) 1992-09-17
AU5200096A (en) 1996-07-18
CA2062091C (en) 2002-12-17
JP3436537B2 (ja) 2003-08-11
HU222487B1 (hu) 2003-07-28
AU669654B2 (en) 1996-06-20
DE69232126T3 (de) 2008-07-17
NZ241778A (en) 1995-04-27
KR100227002B1 (ko) 1999-10-15
IL101113A0 (en) 1992-11-15
NO933101D0 (no) 1993-08-31
FI933809A0 (fi) 1993-08-31
EP0502666B1 (de) 2001-10-17
AU689035B2 (en) 1998-03-19
IE920660A1 (en) 1992-09-09
NO933101L (no) 1993-10-19

Similar Documents

Publication Publication Date Title
Proesmans et al. Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes
Fu et al. Bioavailability of tocotrienols: evidence in human studies
Mitra et al. Cholesterol solubilization in aqueous micellar solutions of quillaja saponin, bile salts, or nonionic surfactants
IL87149A (en) 6-Piperazinyl derivatives of purine and its 3- and 9-deaza isosteres, their preparation and pharmaceutical compositions containing them
BR9612693A (pt) Composição de estanol e uso da mesma.
BRPI0412241A (pt) formulação para medicamentos de proteìna sem adição de albumina de soro humano (hsa)
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE69114498D1 (de) Kurzbettige, einfach ungesättigte fettsäuren enthaltende nahrungsmittel und pharmazeutische zusammensetzungen sowie deren anwendungen.
BR9507846A (pt) Composição farmacéutica estável e fortemente concentrada de principio ativo da classe dos taxóides escolhido entre o docetaxol ou os derivados do docetaxol processo de preparação desta composição e utilização de uma solução congelada ou liofilizada
BR9713645A (pt) Produto de pele tendo propriedade contìnuas anti-microbial, anti-viral, anti-séptico e de cicatrização.
AU669654B2 (en) Pharmaceutical compositions and uses of water-soluble, high-viscosity grade cellulose ethers
BR9401199A (pt) Preparados de medicamentos, processo para a preparação de um preparado de medicamento, processo para a preparação de uma formulação de medicamento.
BR0309421A (pt) Composições de proteìna associada com corpo oleoso e métodos de uso destas para reduzir o risco de doença cardiovascular
AU8119491A (en) Novel piperidyl ethers and thioethers as inhibitors of cholesterol biosynthesis
RU2108788C1 (ru) Лекарственное средство для профилактики и лечения нарушений липоидного и холестеринового обмена веществ
KR930001903A (ko) 유비데카레논 경구용 수용액 제제
TR200100897T2 (tr) Lipid metabolizma bozukluklarının tedavisinde safra asitleriyle bağlı propanolamin türevleri.
UY25510A1 (es) Procedimiento para la producción de preparados efervescentes
KR880003628A (ko) 처리된 리피드 조절제
BRPI0413714A (pt) frações de leite e preparações de leite para tratamento e/ou prevenção de doenças mediadas por cox-2
US20060034945A1 (en) Composition for restoring damaged skin
SE8403659D0 (sv) Synergistic pharmaceutical composition
Backes et al. Modified‐policosanol does not reduce plasma lipoproteins in hyperlipidemic patients when used alone or in combination with statin therapy
Brunner et al. Effect of simulated weightlessness on phase II drug metabolism in the rat
BR0115506A (pt) Composições farmacêuticas tendo uma ação antidiabética, e processo para sua preparação

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties